Investors·2026-01-21 15:18Core Viewpoint - Johnson & Johnson (JNJ) stock experienced a decline despite the company providing strong guidance for 2026, primarily due to competitive pressures from Boston Scientific (BSX) and Medtronic (MDT) in the electrophysiology sector [1] Company Summary - Johnson & Johnson's electrophysiology business is facing challenges as competitors Boston Scientific and Medtronic continue to undercut its market position [1] - The company has issued strong guidance for 2026, indicating confidence in its future performance despite current stock fluctuations [1] Industry Summary - Electrophysiology tools, which include pulsed field ablation (PFA), are critical for studying heart rhythms and treating conditions like atrial fibrillation [1] - PFA utilizes high-voltage electrical pulses to eliminate problematic heart tissue, thereby restoring normal heart rhythm [1]